HC Wainwright Analysts Increase Earnings Estimates for TVTX

Travere Therapeutics, Inc. (NASDAQ:TVTX) – Equities researchers at HC Wainwright boosted their FY2027 earnings per share estimates for Travere Therapeutics in a research report issued on Monday, November 10th. HC Wainwright analyst J. Pantginis now forecasts that the company will earn $2.55 per share for the year, up from their prior estimate of $0.95. HC Wainwright has a “Buy” rating and a $47.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($1.40) per share. HC Wainwright also issued estimates for Travere Therapeutics’ FY2028 earnings at $4.67 EPS and FY2029 earnings at $5.70 EPS.

Travere Therapeutics (NASDAQ:TVTX) last issued its quarterly earnings data on Thursday, October 30th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.59. The firm had revenue of $113.15 million for the quarter, compared to analysts’ expectations of $106.09 million. Travere Therapeutics had a negative net margin of 50.64% and a negative return on equity of 717.68%. The business’s quarterly revenue was up 162.1% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.70) EPS.

Several other research analysts also recently commented on the company. Piper Sandler raised their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Citigroup lifted their price target on shares of Travere Therapeutics from $34.00 to $48.00 and gave the company a “buy” rating in a report on Friday, October 31st. Wall Street Zen raised shares of Travere Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday. TD Cowen lifted their target price on shares of Travere Therapeutics from $30.00 to $40.00 and gave the company a “buy” rating in a research note on Friday, October 31st. Finally, Jefferies Financial Group set a $35.00 price target on Travere Therapeutics in a research note on Wednesday, September 10th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.71.

Travere Therapeutics Stock Performance

NASDAQ TVTX traded up $0.20 on Wednesday, hitting $36.31. 25,450 shares of the company traded hands, compared to its average volume of 1,825,739. The business’s 50 day moving average price is $26.81 and its 200-day moving average price is $20.29. Travere Therapeutics has a 52-week low of $12.91 and a 52-week high of $36.76. The company has a current ratio of 2.00, a quick ratio of 1.98 and a debt-to-equity ratio of 9.50. The company has a market capitalization of $3.25 billion, a price-to-earnings ratio of -17.74 and a beta of 0.90.

Institutional Trading of Travere Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Raymond James Financial Inc. purchased a new position in Travere Therapeutics during the second quarter worth $33,000. First Horizon Corp purchased a new position in shares of Travere Therapeutics during the 3rd quarter worth about $36,000. Caitong International Asset Management Co. Ltd bought a new position in Travere Therapeutics during the 1st quarter valued at about $62,000. Headlands Technologies LLC purchased a new stake in Travere Therapeutics in the 2nd quarter worth about $73,000. Finally, Atria Investments Inc purchased a new stake in Travere Therapeutics in the 2nd quarter worth about $154,000.

Insider Buying and Selling at Travere Therapeutics

In related news, CAO Sandra Calvin sold 67,115 shares of Travere Therapeutics stock in a transaction dated Tuesday, November 4th. The stock was sold at an average price of $36.00, for a total value of $2,416,140.00. Following the completion of the transaction, the chief accounting officer owned 48,545 shares in the company, valued at approximately $1,747,620. This trade represents a 58.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric M. Dube sold 92,872 shares of the company’s stock in a transaction that occurred on Tuesday, October 28th. The shares were sold at an average price of $30.38, for a total value of $2,821,451.36. Following the sale, the chief executive officer owned 419,173 shares in the company, valued at approximately $12,734,475.74. This trade represents a 18.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 223,941 shares of company stock valued at $7,221,380 over the last ninety days. Corporate insiders own 4.19% of the company’s stock.

Travere Therapeutics Company Profile

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.